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Chao Qin1,2, Xiaoyan He3, Yanding Zhao4, Chun-Yip Tong2, Kenneth Y. Zhu5, Yongqi Sun1* and Chao Cheng2*

Abstract
Background: Neuroblastoma (NB) is the most common extracranial solid tumor found in children. The frequent
gain/loss of many chromosome bands in tumor cells and absence of mutations found at diagnosis suggests that
NB is a copy number-driven cancer. Despite the previous work, a systematic analysis that investigates the
relationship between such frequent gain/loss of chromosome bands and patient prognosis has yet to be
implemented.
Methods: First, we analyzed two NB CNV datasets to select chromosomal bands with a high frequency of gain or
loss. Second, we applied a computational approach to infer sample-specific CNVs for each chromosomal band
selected in step 1 based on gene expression data. Third, we applied univariate Cox proportional hazards models to
examine the association between the resulting inferred copy number values (iCNVs) and patient survival. Finally, we
applied multivariate Cox proportional hazards models to select chromosomal bands that remained significantly
associated with prognosis after adjusting for critical clinical variables, including age, stage, gender, and MYCN
amplification status.
Results: Here, we used a computational method to infer the copy number variations (CNVs) of sample-specific
chromosome bands from NB patient gene expression profiles. The resulting inferred CNVs (iCNVs) were highly
correlated with the experimentally determined CNVs, demonstrating CNVs can be accurately inferred from gene
expression profiles. Using this iCNV metric, we identified 58 frequent gain/loss chromosome bands that were
significantly associated with patient survival. Furthermore, we found that 7 chromosome bands were still
significantly associated with patient survival even when clinical factors, such as MYCN status, were considered.
Particularly, we found that the chromosome band chr11p14 has high potential as a novel candidate cytogenetic
biomarker for clinical use.
Conclusion: Our analysis resulted in a comprehensive list of prognostic chromosome bands supported by strong
statistical evidence. In particular, the chr11p14 gain event provided additional prognostic value in addition to wellestablished clinical factors, including MYCN status, and thereby represents a novel candidate cytogenetic biomarker
with high clinical potential. Additionally, this computational framework could be readily extended to other cancer
types, such as leukemia.
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Background
Neuroblastoma (NB) is the most common extracranial
solid tumor, usually occurring in early childhood, and it
is also the third-most common cancer in babies after
leukemia and brain cancer [1]. It is derived from primitive cells of the sympathetic nervous system and usually
arises in the abdomen or chest [2]. Approximately 25–
50 cases occur per million individuals [3], and 90% of
cases arise in children less than 5 years old [4].
To date, two widely used stage classification systems
for NB patients have been developed to facilitate clinical
research and improve the outcomes of children with NB.
The International Neuroblastoma Staging System (INSS),
developed in 1988, allows the classification of NB patients
into Stage 1, 2A, 2B, 3, 4, and 4S before surgical resection
of the tumor [5]. The International Neuroblastoma Risk
Group Staging System (INRGSS), proposed in 2009,
allows the classification of NB into Stage L1, L2, M and
MS based on the results of imaging tests (CT or MRI and
MIBG scans) before surgery [6]. To help doctors select
the optimal treatment [6], International Neuroblastoma
Risk Group (INRG) combines INRGSS information, histologic category, MYCN status, and other factors to classify
patients into low-, intermediate- and high-risk groups.
Prognostic markers are another important feature used
to help predict the patient’s clinical outlook [7–9]. For
NB patients, many classic prognostic markers, such as
age, tumor histology [10], DNA ploidy [11], transcription
instability [12], and MYCN amplification [13–15] have
been used to predict the prognostic outcome of patients.
Among them, MYCN is the most critical prognostic
marker in NB patients. MYCN is a master transcription
factor that activates growth-sustaining genes and represses
genes that drive differentiation [14]. MYCN amplification
is found in approximately 25% of all tumors, and most
malignant NB patients exhibit MYCN amplification [16].
Many studies report the gain of 1q, 2p, and 17q along
with a loss of 1p, 3p, 4p, 14q, 11q, 17q, and 19q in the
genomes of NB patients (reviewed in [17, 18]). Deletion
of chr1p36 occurs in 23–35% of patients [19–21], and
deletion of 11q23 occurs in 26–44% of patients [21–23];
each is associated with poor prognosis. The frequent
chromosome segment gains and losses [24, 25] but few
mutations have been found in NB tumor samples, suggesting that NB is a copy number-driven cancer [17, 26].
Nevertheless, a systematic analysis for the identification
of prognostic-associated chromosome bands with frequent gain/loss events for NB patients is still lacking and
will be helpful for clinicians in treatment selection.
In this study, we took advantage of the abundant NB
genomic data (gene expression data, copy number variation (CNV) data, and clinical information) to systematically identify chromosomal aberration events (gains or
losses) that were associated with the clinical outcomes of
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NB patients. Our analyses revealed a number of chromosomal bands that were frequently amplified or deleted in
NB samples with significant associations at the prognostic level. Particularly, some bands (chr11q23, chr11p14)
were still predictive of patient survival after adjusting for
well-established clinical variables, including MYCN amplification status, an extremely widely used prognostic biomarker. These chromosomal aberrations have the potential
to be developed into effective cytogenetic markers, as they
are visible by microscopic examination. Such a marker can
further improve prognostic prediction and patient stratification in NB. Moreover, the computational framework
introduced in this article can be readily applied to the identification of cytogenetic markers in other cancer types.

Methods
Dataset and data processing

NB gene expression datasets and related clinical data with
sufficient overall outcome information were downloaded
from the Gene Expression Omnibus (GEO) under accession number GSE62564 (Su et al., n = 498). The International Cancer Genome Consortium (ICGC) data portal
was accessed under the code NBL-US (Pugh et al., n =
249), which contained the segmental chromosome CNV
data. The European Bioinformatics Institute was accessed
under ID: E-MTAB-179 (Oberthuer et al., n = 478). The
other dataset used in this study that did not contain survival information was downloaded from the GEO under
accession number GSE45478 (Kocak et al., n = 123) with
the NB segmental CNV information and gene expression
profiles. Among them, GSE62564 was generated using the
RNA-seq platform, NBL-US and E-MTAB-179 using a
one-channel microarray platform, and GSE45478 using a
two-channel array platform. A total of 1347 samples were
included in these datasets. A summary of these four datasets is provided in Additional file 8: Table S8. The gene
expression values obtained from the RNA-seq platform
and the one-channel microarray platform were log transformed, and gene-wise mean normalization was performed to obtain the relative expression values for these
datasets. The genes associated with positional gene set
data were downloaded from the C1 collection of MSigDB
(http://software.broadinstitute.org/gsea/msigdb/index.jsp)
[27], all bands from the X and Y chromosomes were
excluded.
Mapping the segmental chromosome’s CNV to the
chromosome band’s CNV

For each sample, the segmental chromosome’s CNV was
mapped to the chromosome band’s CNV. The CNV of
chromosome band i is defined as follows:
CNV ðiÞ ¼

Xn
j¼1

lij
SCNV ð jÞ;
li
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where SCNV(j) is the CNV value of the jth segment
chromosome, li is the length of chromosome band i, lij is
the length of the overlap between the chromosome band
i and the segmental chromosome j, and n is the number
of the segmental chromosomes in a given sample.
Calculation of chromosome band CNV (iCNV) based on
the gene expression data

For a given gene expression dataset, all the genes located
on a given chromosome band were grouped into a set
designated ‘B’, and the rest of the genes located on any
other chromosome bands were grouped into a set designated ‘A’. The inferred CNV for a given chromosome
band is the value of Student’s t statistic comparing the
gene sets B and A:
xB −xA
t ¼ sﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ


2
s2B
s
A
þ
nB
nA
where x is the mean, s2 is the variance, and n is the
number of genes located in a gene set [28]. For each
sample in the dataset, this process was iterated for each
chromosome band such that we obtained a matrix of
iCNVs for each chromosome band of each sample. If the
number of genes located on a chromosome band was less
than 10, we considered the Student’s t statistic measurement unreliable, and that chromosome band was eliminated from further analysis.
Survival analysis

A univariate Cox proportional hazards model was fitted
to the iCNV for each chromosome band across all samples in a dataset to evaluate the relationship between
iCNV and sample survival time. For survival-associated
iCNVs of chromosome bands, multivariate Cox proportional hazards models were used to examine prognostic
abilities, while potential confounding factors, including
MYCN status, age, gender, and stage were considered.
Kaplan-Meier curves were used to visualize the results
from the Cox proportional hazards model. Specifically,
the iCNVs were stratified into two groups by the median
value for generating the Kaplan-Meier curves.
All survival analyses were conducted in R using the
“survival” package. Specifically, “coxph”, “survfit”, and
“surdiff” were called to create the Cox proportional hazards model, plot Kaplan-Meier curves, and compare the
two survival curves.

Results
Overview of this study

To systematically identify novel candidate cytogenetic
biomarkers, we performed an integrative analysis via the
following main steps (Fig. 1). First, we analyzed two NB
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CNV datasets to select chromosomal bands with a high
frequency of gain or loss. One of the datasets included
samples from all stages [29], while the other included
only high-risk NB samples (mostly Stage IV) [30]. By
combining results from both datasets, we selected 223
chromosomal bands with > 15% gain/loss frequency in at
least one of the datasets. Second, we applied a computational approach to infer sample-specific CNVs for each
chromosomal band selected in step 1 based on gene
expression data. This approach was applied to Su [31]
and Oberthuer [32] NB datasets, which contained both
gene expression profiles and clinical information, particularly the survival times of patients. Third, we applied
univariate Cox proportional hazards models to examine
the association between the resulting inferred copy number values (iCNVs) and patient survival. Finally, we
applied multivariate Cox proportional hazards models to
select chromosomal bands that remained significantly
associated with prognosis after adjusting for critical clinical variables, including age, stage, gender, and MYCN
amplification status. Of note, we used gene expression
data rather than CNV data to determine the association
between chromosomal bands and patient survival. We
selected gene expression data because more gene expression data are available with a significantly larger sample
size and higher quality of survival information than
CNV data, thus ensuring sufficient statistical power and
rigorous results of our analysis.
CNV data analysis identified chromosome bands with a
high frequency of gain or loss

To identify chromosome bands that were frequently amplified or deleted in NB patients, we analyzed two CNV datasets. Each dataset identified chromosomal segments with
abnormal copy numbers determined using array-based
comparative genomic hybridization and genome-wide
human single nucleotide polymorphism (SNP) arrays 6.0,
respectively. One dataset contained 122 samples from different stages (the Kocak dataset) [29], and the other dataset
focused on high-risk NB samples, including 149 out of 150
from Stage IV tumors (the Pugh dataset) [30].
By combining the two datasets, our analysis included
chromosome bands with high gain/loss frequency generally in all samples and in high-risk samples. Specifically,
for each sample, we mapped the aberrant segments to
chromosome bands and obtained copy number values of
each band (see Additional file 1: Table S1). In Fig. 2a
and b, we summarized the frequency of gain/loss for
each chromosome band (272 in total excluding the X
and Y chromosomes) in the two datasets. As expected,
there was a negative correlation between amplification
and deletion frequency. Namely, a set of chromosome
bands was frequently amplified in NB with high frequency, while a different set of bands was frequently
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Fig. 1 Schematic diagram of our analysis. a The segmental chromosome copy number variation data of neuroblastoma patients was used to
map to the chromosome band copy number variation, and the frequency of chromosome band gain/loss was obtained. We selected
chromosome bands with a gain/loss frequency > 15% as the frequent gain/loss chromosome bands. b The neuroblastoma patient gene
expression profiles were used to calculate the inferred copy number variation (iCNV) of each chromosome band. c A Cox proportional hazard
model was used to measure the correlation between frequent gain/loss chromosome band iCNVs and patient survival time

deleted. This enabled us to define frequently amplified
and frequently deleted chromosome band sets. By setting
the cut-off values to 15%, we identified 118 frequently
amplified bands and 96 frequently deleted bands in the
Kocak dataset and 70 frequently amplified bands and 61
frequently deleted bands in the Pugh dataset (Fig. 2c).
Although the observed gain/loss frequency was highly
consistent, some chromosome bands had notable differences between the two datasets, indicating variations in

chromosome aberration events among tumor stages. For
example, chr1p36 was lost in 16% of samples in the
Kocak dataset but was lost in as high as 36% of Stage IV
samples (the Pugh dataset). To obtain a comprehensive
list of chromosome bands with high frequency gain/loss
events, we took the union of the bands identified from
the two datasets, yielding 125 and 105 frequently amplified and frequently deleted chromosome band sets,
respectively (Fig. 2c) (Additional file 2: Table S2). Most
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Fig. 2 Chromosome band gain/loss frequency in the Kocak and Pugh datasets. a The frequency of chromosome band gain/loss on the Kocak
dataset, which contains all six stages of neuroblastoma patients. Chromosome bands on the right side of the vertical dashed line or above the
horizontal dashed line are considered frequent gain/loss on the Kocak dataset. b The chromosome band gain/loss frequency in the Pugh dataset,
which contained 1 Stage I patient and 149 Stage IV patients. Chromosome bands on the right side of the vertical dashed line or above the
horizontal dashed line were considered to have frequent gain/loss in the Pugh dataset. c The number of frequent gain/loss chromosome bands
in the Kocak and Pugh datasets. The association of these 223 chromosome bands with frequent gain/loss events with patient survival was studied

of the previously established cytogenetic markers are
included in our band sets. For example, the well-known
chr17q21 [33, 34] was amplified in 95% (the Kocak dataset) and 74% (the Pugh dataset) of samples, while
chr11q23 [35, 36] was deleted in 40% (the Kocak dataset) and 49% (the Pugh dataset) of samples.
Interestingly, between the frequently amplified and frequently deleted chromosome band sets, there were 7
overlapping chromosome bands. These 7 chromosome
bands were chr11p15, chr11p14, chr11p13, chr11p12,
chr11p11, chr11q11, and chr11q12. In the Kocak dataset,
they were more likely to be deleted. In the Pugh dataset,
they were more likely to be amplified. It is notable that
all these chromosome bands are from chromosome 11.
Thus, we examined the co-occurrences of the grain/loss
events of these bands in samples from the Kocak and
Pugh datasets (Additional file 9: Figure S1 and S2). Out
of the 60 samples in the Kocak dataset, 34 are associated
with whole-chromosome gain (n = 3) or loss (n = 31) of
chromosome 11,45 with whole-arm gain (n = 13) or loss
(n = 32) of chromosome 11p, and 34 with whole-arm
gain (n = 3) or loss (n = 31) of chromosome 11q. Out of
the 167 samples in the Pugh dataset, 43 are associated
with whole-chromosome gain (n = 7) or loss (n = 36) of
chromosome 11, 90 with whole-arm gain (n = 48) or loss
(n = 42) of chromosome 11p, and 45 with whole-arm
gain (n = 7) or loss (n = 38) of chromosome 11q.
We noted that many of these chromosome bands were
consecutive in the genome, e.g., chr1p36, chr1p35, chr1p34,
and chr1p33. The chromosome bands from the same clusters were likely associated with the same chromosome
gain/loss hot spot. Thus, we produced a list of nonredundant chromosome bands by selecting the most frequently

gained or lost bands from each cluster, resulting in a total
of 29 frequently amplified and 29 frequently deleted nonredundant bands (Additional file 3: Table S3).
Copy numbers of chromosome bands can be accurately
inferred from gene expression data

To identify cytogenetic events of potential prognostic
value, we aimed to examine the association between
chromosome band gain/loss events and patient survival in
a systematic manner. The above-described Kocak CNV
dataset did not provide patient survival information and
therefore could not be used for this analysis. The Pugh
CNV dataset comprised mostly high-risk patients. However, a few high-quality gene expression datasets from NB
patients were generated, which provided expression profiles for a large number of tumor samples and carefully
prepared survival information (Additional file 4: Table S4).
Therefore, we adapted a previously proposed method [28]
to infer the copy number of chromosome bands based on
these high-quality gene expression datasets. This method
compared the expression of genes located in a chromosome band against other genes and used the Student’s t
statistic to infer the chromosome band status. This
analysis resulted in an inferred copy number value (iCNV)
for each chromosome band in each tumor sample.
First, we assessed the performance of this method by
comparing the iCNVs to experimentally measured copy
number scores using the Kocak dataset. As shown in
Fig. 3a, we selected three samples with amplified, normal
and deleted chr1p36. The expression of genes in this
chromosome band reflected the band status with high fidelity. The iCNVs for this band were also highly correlated (R = 0.97) with the experimentally determined copy
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Fig. 3 Correlation between chromosome band inferred copy number variation (iCNV) and copy number variation (CNV). a The gene expression
profile of three patients with gain, normal, and loss of Chr1p36. Genes are sorted according to their position on the chromosome. b The
correlation between iCNV and CNV of Chr1p36 for all samples. c A histogram for the correlation coefficient of chromosome bands across all
samples. d The correlation matrix heatmap of the chromosome bands across all samples

numbers (Fig. 3b). We then calculated the correlation coefficients for all of the 272 chromosome bands, and their
distribution indicated a high accuracy of the copy number
inference (Fig. 3c). More than 80% of chromosome bands
had R > 0.8. Moreover, iCNVs for any particular band had
the highest correlation with the measured copy number
scores of the same band but had much lower correlations
with other bands, indicating high specificity (Fig. 3d).
Taken together, our results suggested that the iCNV inferred from gene expression data provided an accurate estimation of chromosome band copy numbers.

Identification of chromosome bands associated with
patient prognosis

We then applied the chromosome band copy number
inference method to two gene expression datasets, Su
[31] and Oberthuer [32], to calculate sample-specific
iCNVs. Subsequently, we examined the iCVNs for their
association with prognosis. We focused our analysis on
the 125 frequently amplified and 105 frequently deleted
chromosome bands. We used univariate Cox proportional hazard models to identify chromosome bands that
were significantly associated with patient survival. As
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shown in Fig. 4a, the gain/loss status of the 223 chromosome bands and the prognostic association with patient
survival for the two datasets are briefly described. To obtain a list of prognostic chromosome bands of highest
confidence, we combined the results from these two
datasets and selected the bands that were significant in
all datasets (adjusted p < 0.05) (Fig. 4b). This combination of results yielded a total of 58 significant chromosome bands (Additional file 5: Table S5). Among the 27
frequently amplified bands, 24 were associated with good
survival (HR < 1), and three were associated with poor survival (HR > 1). Among the 31 frequently deleted bands, 22
were associated with good survival (HR < 1), and 9 were
associated with poor survival (HR > 1) (Fig. 4c). Detailed
information on the 58 prognostic-associated bands is
shown in Fig. 4d. Most of the chromosomal bands with
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aberration events were clearly associated with good prognosis (46/58). Furthermore, we found that most of these
bands were either hot spots or near the hot spots, suggesting the importance of each hot spot area in terms of patient prognosis. We further selected four chromosome
bands as examples, as shown in Fig. 5a, b. The loss of
chr1p36 was associated with poor prognosis in both the
Su and Oberthuer datasets, and this finding was consistent
with previous reports [37, 38]. We also found that the loss
of chr14q22 was associated with good prognosis. The
gains of chr12q22 and chr7q31 were associated with poor
prognosis and good prognosis, respectively.
It is important to note that the status of MYCN, the
best-characterized genetic marker associated with poor
prognosis in NB [14], may confound our results. To further examine whether the prognostic association of these

Fig. 4 Fifty-eight robust chromosome bands were associated with patient survival. a An overview of the 272 chromosome bands with frequency
of gain/loss events and prognosis. Track a shows a histogram of the gain/loss frequency in the Pugh dataset. Track b shows a histogram of the
gain/loss frequency in the Kocak dataset. Track c shows the gain/loss status for each chromosome band. Dark purple represents frequent gain.
Light purple represents frequent loss. Gray represents nonfrequent gain/loss. Track d shows the association between chromosome aberration and
prognosis in the Su dataset. Green presents the high frequency of gain/loss chromosome bands associated with prognosis. Gray presents nonassociation with prognosis. Track e shows the association between chromosome aberration and prognosis in the Oberthuer dataset. Red presents
chromosome bands with high gain/loss frequency associated with prognosis. Gray presents non-association with prognosis. b The overlapping
prognostic-associated chromosome bands in the Su and Oberthuer dataset. c The number of frequent gain/loss chromosome bands associated
with good/bad outcome. d Detailed information on the 58 robust chromosome bands associated with patient survival
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Fig. 5 Prediction applications of the iCNV of chromosome bands in the Su and Oberthuer datasets. Loss of chr1p36 and gain of chr12q22 were
associated with poor prognosis in both the Su (a) and Oberthuer (b) datasets. Loss of chr14q22 and gain of chr7q31 were associated with good
prognosis in both the Su (a) and Oberthuer (b) datasets

58 chromosome bands was independent of this clinical
variable, we applied multivariate Cox proportional hazard models to the Su and Oberthuer datasets. The
models included sample-specific iCNV for each band,
stage, age, gender and status of MYCN status as covariates. We selected the chromosome bands with Cox proportional hazards p-value < 0.05 in these two datasets
which yielded 7 chromosome bands with iCNV associated with patient survival (Additional file 6: Table S6).
Taking the well-known cytogenetic marker chr11q23
as an example in the Su dataset, loss of chr11q23 was associated with poor prognosis, which was also consistent
with a previous report [35] (Fig. 6a). After we considered
potential confounding clinical variables including MYCN
status, stages, sex, and age, using a multivariate Cox proportional hazard model, the iCNV for chr11q23 remained
significant (p = 2e-04) with a hazard ratio of 1.13 (Fig. 6b).
To further examine whether the iCNV for chr11q23 was
still significant with patient prognosis in both the MYCN
amplification patient cohort and the MYCN nonamplification patient cohort, we compared the survival curves of four
groups stratified based on the level of iCNV and MYCN
status (Fig. 6c). The iCNV for chr11q23 was still significantly associated with poor prognosis in the MYCN nonamplification patient cohort (p = 3e-06, HR = 4.49) while
was less significant in the MYCN amplification patient
group. We also performed these analyses on the Oberthuer
dataset and obtained similar results (Fig. 6d, e, f).
In addition to chr11q23, among the seven chromosome
bands, we found that chr11p14 was also a potential novel

cytogenetic marker for measuring the progress of NB
patients. Chr11p14 was an interesting chromosome band
that exhibited a character different from most of the other
chromosome bands. It exhibited not only loss events but
also gain events. The frequency of gain events in the Pugh
dataset was 18%, but the frequency of loss events in the
Kocak dataset was 26%. As shown in Fig. 7a, the gain
events for chr11p14 were significantly associated with
poor prognosis (p = 3e-10, HR = 3.905) in the Su dataset.
Furthermore, a significant result was obtained upon
applying the multivariate Cox proportional hazard
model, as described above (Fig. 7b, p = 1e-04, HR =
1.337). Additionally, among the MYCN nonamplification patients, the gain of chr11p14 was significantly
associated with poor prognosis (Fig. 7c, p = 5e-06,
HR = 4.151). To further validate our results, we performed the same analysis on the Oberthuer dataset
and obtained similar results (Fig. 7d, e, f).
The Pugh dataset differs from the two datasets
described above; most of the samples in this dataset are
Stage IV (216 Stage IV, 1 Stage III and 30 Stage I). To
further investigate the association between chromosome
band gain/loss and high-risk status for patients, we
applied a univariate Cox proportional hazard model and
found 10 prognosis-associated chromosome bands (adjust p < 0.05) (Additional file 7: Table S7). Seven of the
10 bands were also discovered in the other two datasets
(Su and Oberthuer datasets). The other 3 chromosome
bands were discovered in either the Su dataset or the
Oberthuer dataset.
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Fig. 6 iCNV of chr11q23 as a predictor of survival in Su and Oberthuer datasets. a, d Loss of chr11q23 was associated with poor outcome in the
Su and Oberthuer datasets. b, e The iCNV of chr11q23 was significantly associated with poor prognosis after taking into account several
confounding factors in the two datasets. c, f The iCNV of chr11q23 was still significant among MYCN nonamplification patients and predicted
poor prognosis in the Su and Oberthuer datasets

Taken together, our analysis resulted in a comprehensive list of prognostic-associated chromosome bands. In
particular, the chr11p14 gain event provided additional
prognostic value in addition to well-established clinical
factors, including MYCN status, and thereby represents
a novel candidate cytogenetic biomarker with high clinical potential.

Discussion
Chromosomal instability is a hallmark of human cancer
and plays an important role during tumorigenesis and
progression [39]. Frequent gain or loss of particular
chromosome regions has been investigated in certain
cancer types, such as leukemia and NB [40, 41]. Some of
these recurrent events have been developed into cytogenetic markers to define cancer subtype, predict prognosis, and select effective therapeutic interventions [42].
A list of chromosome aberration events in NB was previously compiled [17]. For example, deletion of chr1p36
[19] and chr11q23 [21] have been reported in 23–35%
and 26–44% NB samples, respectively. Both deletions
were associated with poor prognosis. Conversely, whole
gain of chr17q is associated with good prognosis [34].

Despite the important clinical implications and extensive
reports in previous studies, the association of chromosome bands with prognosis has never been investigated
in a systematic manner. In this study, we integrated different genomic data with clinical information to systematically identify novel candidate cytogenetic markers for
improving NB prognosis.
We utilized two CNV datasets to identify chromosome
bands with a high frequency of gain or loss events in
NB. This could theoretically also be achieved by examining the iCNV inferred from gene expression data. The
iCNV is an essential t statistic that compares the relative
expression levels of genes in a chromosome band with
those not in that chromosome band. As such, each
iCNV was associated with a p-value that could be estimated by referring to the t distributions. Given an NB
gene expression dataset, we might calculate samplespecific iCNVs along with corresponding p-values and
then count the number of samples in which a band
shows significantly higher (gain) or lower (loss) iCNV.
However, the frequency of a gain/loss event can only be
correctly calculated if the relative expression levels of
genes were calculated by normalizing against their
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Fig. 7 Chr11p14 as a potential cytogenetic marker for predicting survival in the Su and Oberthuer datasets. a, d Gain of chr11q23 was associated
with poor outcome in the two datasets. b, e The iCNV of chr11p14 was significantly associated with poor prognosis after taking into account
several confounding factors in the two datasets. c, f The iCNV of chr11p14 was still significantly associated with poor prognosis among MYCN
nonamplification patients in the two datasets

expression in normal tissue. Unfortunately, no normal
control was available in the NB gene expression datasets.
Therefore, in our analyses, we used the median expression of genes in all samples to convert absolute gene expression values to relative expression values, which has
been proposed in [12]. For this reason, the iCNV calculated from these datasets indicated the copy numbers
relative to the median reference rather than a normal
control and did not correctly inform the gain/loss frequency of chromosome bands. On the other hand, the
iCNV remained effective for examining the association
with patient prognosis.
The CNV datasets were not used in our analysis to determine the association of chromosome band gain/loss
events with prognosis because of their limitations. The
Kocak dataset did not provide survival information, and
the Pugh dataset contained only Stage IV NB samples
(expect for 1 Stage III sample). In contrast, the gene
expression datasets used in our analysis were originally
produced for prognostic studies and had large sample
sizes. For example, the Su dataset was generated by the
SEQC Project, containing 498 carefully selected NB samples with detailed clinical information, including patient

survival. In addition, the Su and Oberthuer datasets contained samples from all stages. Combined with the high
risk-specific Pugh dataset, these gene expression datasets
enabled us to systematically identify chromosome bands
that were prognostic in all NB patients or found specifically in high-risk (most Stage IV) patients. Moreover, by
combining results from multiple independent datasets, we
expected to obtain a list of highly confident prognosticassociated chromosome bands for cytogenetic marker
development.
MYCN amplification correlates with high-risk disease,
has been found in ~ 25% of NB patients, and is widely
used as the most critical prognostic marker. For highrisk NB patients, the 5-year survival rate is approximately 40 to 50%. After considering the MYCN status,
we still found 7 chromosome bands significantly associated
with patient survival. Chr11q23 has been well studied.
However, gain of chr11p14 was significantly associated
with poor prognosis, which has the potential to be a novel
cytogenetic biomarker. In the high-risk group (Pugh dataset), we identified 10 chromosome bands associated with
patient outcomes that were also found in the other two
datasets.
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Conclusions
In conclusion, we performed a systematic analysis that
integrated different genomic datasets with clinical information to identify chromosome band gain or loss events
associated with NB patient prognosis. Our analysis
resulted in a comprehensive list of prognostic chromosome bands supported by strong statistical evidence. In
particular, the chr11p14 gain event provided additional
prognostic value in addition to well-established clinical
factors, including MYCN status, and thereby represents
a novel candidate cytogenetic biomarker with high clinical potential. Additionally, the computational framework introduced in this article could be readily extended
to other cancer types, such as leukemia.
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